Potential effect of metformin and vildagliptin against isoniazid induced hepatotoxicity in Wistar albino rats

Shoba S.; Jeeva T.; Lokesh J.; Narmatha M.; Nithyasri E.; Rohith  Kannan A.

doi:10.18203/2320-6012.ijrms20241243

Authors

Shoba S. Department of Pharmacology, Adhiparasakthi College of Pharmacy, Melmaruvathur, India
Jeeva T. Department of Pharmacology, Adhiparasakthi College of Pharmacy, Melmaruvathur, India
Lokesh J. Department of Pharmacology, Adhiparasakthi College of Pharmacy, Melmaruvathur, India
Narmatha M. Department of Pharmacology, Adhiparasakthi College of Pharmacy, Melmaruvathur, India
Nithyasri E. Department of Pharmacology, Adhiparasakthi College of Pharmacy, Melmaruvathur, India
Rohith Kannan A. Department of Pharmacology, Adhiparasakthi College of Pharmacy, Melmaruvathur, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241243

Keywords:

Hepatoprotective, Metformin, Vildagliptin, INH, Liver enzymes

Abstract

Background: Metformin and vildagliptin both are anti-diabetic agent and they play an important role in diabetic patients as they reduce blood glucose levels. Studies revealed that both metformin and vildagliptin has the ability to promote beta cell neogenesis and regeneration. So, our study was planned to explore the hepatoprotective potential of metformin and vildagliptin in Wistar albino rats exposed to isoniazid (INH) induced hepatotoxicity.

Methods: Wistar albino rats weighing 150-180 g were obtained from Mass Biotech, Chengalpattu, Tamil Nadu. The animals were divided into 6 groups (n=6) and further treated orally against INH-induced hepatotoxicity except normal control group. group 1: normal control, group 2: INH, group 3: metformin+INH, group 4: vildagliptin+INH, group 5: metformin amd vildagliptin+INH, group 6: silymarin.

Results: In the present study, INH was administered for 21 days to induce liver damage to rats except normal group. Each group was treated with metformin, vildagliptin, (metformin+vildagliptin) combination and silymarin half an hour before INH challenge. On the 22nd day the blood samples were collected to estimate the AST and ALT levels. Immediately after blood collection the animals were sacrificed, the livers were removed and kept in 10% formalin for histopathological examination.

Conclusions: The study found that metformin, vildagliptin, and their combination showed hepatoprotective activity against INH-induced hepatotoxicity. The combination of metformin+vildagliptin was the most effective. Metformin reduces oxidative stress, while vildagliptin balances pro-oxidant and anti-oxidant levels, contributing to their hepatoprotective effects. This suggests their potential usefulness in drug-induced hepatotoxicity.

Metrics

Metrics Loading ...

References

Ward FM, Daly M. Hepatic Disease. Clinical Pharmacy and Therapeutics. In: Walker R, Clive C, eds. 2nd ed. London: Churchill Livingstone, Harcourt Brace and Company Limited; 1999: 195.

Dienstag JL, Isselbacher KJ. Toxic and drug-induced hepatitis. Harrison's Principles of Internal Medicine. In: Braunwald E, eds. 15th ed. McGraw-Hill Companies, Inc.; 2001: 1737-42.

Speight TM, Holford NH. Gastrointestinal and Hepatic Diseases. Avery's Drug Treatment. 4th ed. New Zealand: Adis International Limited; 1997: 937.

Bhanwra S, Singh J, Khosla P. Effect of Azadirachta indica leaf aqueous extract on paracetamol-induced liver damage in rats. J Physiol Pharmacol. 2000;44(1):64-8.

Dass EE, Shah KK. Paracetamol and conventional antimalarial drugs induced hepatotoxicity and its protection by methionine in rats. Indian J Exp Biol. 2000:1138-42.

Saraswathy SD, Suja V, Gurumurthy P, Shyamala Devi CS. Effect of Liv-100 against anti-tubercular drugs (isoniazid, rifampicin and pyrazinamide) induced hepatotoxicity in rats. Ind J Pharmacol. 2013;30(4):233-8.

Davies DM. Text Book of Adverse Drug Reactions. 3rd ed. New York: Oxford University Press; 1985: 253-65.

Johnson-Fannin AMS. Hepatitis: viral and drug induced. Text Book of Therapeutics Drug and Disease Management. In: Herfindal ET, Gourley DR. 6th ed. USA: Williams and Wilkins; 1996: 543-4.

Bishayee A, Sarkar A, Chatterjee M. Hepatoprotective activity of Carrot (Daucus carota 1) against carbon tetrachloride intoxication in mouse liver. J Ethnopharmacol. 1995;47:69-74.

Balasubramaniam P, Pari L, Menon VP. Protective effect of carrot (Daucus carota L.) against lindane- induced hepatotoxicity in rats. Phytother Res. 1998;12:434-36.

Gulati RK, Agarwal S, Agrawal SS. Hepatoprotective studies on Phyllanthus emblica Linn. and quercetin. Indian J Exp Biol. 1995;33(4):261-8.

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577-85.

Yimer EM, Surur A, Wondafrash DZ, Gebre AK. The effect of metformin in experimentally induced animal models of epileptic seizure. Behav Neurol. 2019:2019:6234758.

Chen S, Gan D, Lin S, Zhong Y, Guozhi. Metformin in aging and anti-aging related diseases. clinical application and relevant mechanism. Theranostics. 2022;12(6):2722-40.

Johnson NP. Metformin use in women with polycystic ovary syndrome. Ann Translation Med. 2014;2(6):56.

Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathya S. Neuroprotective effect of metformin in mptp-induced Parkinson’s disease in mice. Neuroscience. 2014;274:747-54.

Bu Y, Peng M, Tang X, Xu X, Wu Y, Chen AF, et al. Protective effects of metformin in various cardiovascular diseases: clinical evidence and ampk-dependent mechanisms. J Cell Mol Med. 2022;26(19):4886-903.

Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Experiment Clin Endocrinol Diab. 2013;121(1):27-31.

Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13(9):775-83.

Mostafa RE, Morsi AH, Asaad GF. Anti- Inflammatory effects of saxagliptin and vildagliptin against doxorubicin-induced nephrotoxicity in rats: attenuation of NLRP3 inflammasome up-regulation and tubulo-interstitial injury. Res Pharmaceut Sci. 2021;16(5):547-58.

Trevisan R. The role of vildagliptin in the therapy of type 2 diabetic patients with renal dysfunction. Diabet Ther. 2017;8(6):1215-26.

Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diabetes. 2010;1(1):19-26.

Saravi SSS, Hasanvand A, Shahkarami K, Dehpour RA. The protective potential of metformin against acetaminophen-induced hepatotoxicity in BALB/C mice. Pharmaceut Biol. 2016;54:2830-7.

Argun-Kurum G, Kaya-Dagistanli F, Ozturk M. DPP4 inhibitor induces beta cell regeneration and DDR-1 protein expression as an endocrine progenitor cell marker in neonatal STZ-diabetic rats. Pharmacol Rep. 2019;71(4):721-31.

El-Sherbeeny NA, Nader MA. The protective effect of vildagliptin in chronic experimental cyclosporin a-induced hepatotoxicity. Can J Physiol Pharmacol. 2016;94(3):251-6.

Shoba S, Patil PA, Vivek V. Hepatoprotective activity of Dacus carota L. aqueous extract against paracetamol, isoniazid and alcohol induced hepatotoxicity in male wistar rats. Pharmacology. 2008;3:776-87.

Bayrasheva V, Grineva E, Babenko A, Galagudza M, Chefu S, Dmitriev Y, et al. Vildagliptin alone, and in half- dose combination with Metformin, attenuates streptozotocin-induced diabetic nephropathy in high-fat fed heminephrectomized rats. Endocr Abst. 2014;35(2).

Dahiru D, Obidoa O. Evaluation of the Antioxidant effects of Ziziphus mauritiana Lam. leaf extracts against chronic ethanol-induced hepatotoxicity in rat liver. Afr J Tradit Complement Altern Med. 2008;5(1):39-45.